Tetsuro Ikegami

List of Publications by Year
in descending order

73	4,002	156536	139680
papers	citations	32 h-index	61 g-index

78	78	78	4000
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tilorone-Dihydrochloride Protects against Rift Valley Fever Virus Infection and Disease in the Mouse Model. Microorganisms, 2022, 10, 92.	1.6	2
2	Development of a Simian RNA Polymerase I Promoter-Driven Reverse Genetics System for the Rescue of Recombinant Rift Valley Fever Virus from Vero Cells. Journal of Virology, 2021, 95, .	1.5	7
3	STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV). Viruses, 2021, 13, 1388.	1.5	6
4	Rift Valley Fever Virus and Other Phleboviruses (Phenuiviridae). , 2021, , 765-777.		0
5	Candidate vaccines for human Rift Valley fever. Expert Opinion on Biological Therapy, 2019, 19, 1333-1342.	1.4	19
6	Identification and evaluation of antivirals for Rift Valley fever virus. Veterinary Microbiology, 2019, 230, 110-116.	0.8	10
7	Rescue of infectious Arumowot virus from cloned cDNA: Posttranslational degradation of Arumowot virus NSs protein in human cells. PLoS Neglected Tropical Diseases, 2019, 13, e0007904.	1.3	4
8	Rift Valley fever vaccines: current and future needs. Current Opinion in Virology, 2018, 29, 8-15.	2.6	43
9	Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Scientific Reports, 2018, 8, 7604.	1.6	100
10	Experimental Infection of Syrian Hamsters With Aerosolized Nipah Virus. Journal of Infectious Diseases, 2018, 218, 1602-1610.	1.9	15
11	Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Expert Review of Vaccines, 2017, 16, 601-611.	2.0	42
12	Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection. Journal of Virology, 2017, 91, .	1.5	11
13	Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells. Npj Vaccines, 2017, 2, .	2.9	12
14	Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain. Vaccine, 2017, 35, 6634-6642.	1.7	12
15	Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain. PLoS ONE, 2017, 12, e0185194.	1.1	15
16	Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model. PLoS ONE, 2017, 12, e0189250.	1.1	23
17	Mutational Analysis of the Rift Valley Fever Virus Glycoprotein Precursor Proteins for Gn Protein Expression. Viruses, 2016, 8, 151.	1.5	9
18	N-Glycans on the Rift Valley Fever Virus Envelope Glycoproteins Gn and Gc Redundantly Support Viral Infection via DC-SIGN. Viruses, 2016, 8, 149.	1.5	29

#	Article	IF	Citations
19	Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins. Virology Journal, 2016, 13, 118.	1.4	73
20	Application of Droplet Digital PCR to Validate Rift Valley Fever Vaccines. Methods in Molecular Biology, 2016, 1403, 207-220.	0.4	4
21	Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR. Virulence, 2016, 7, 871-881.	1.8	15
22	The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype. Journal of Virology, 2016, 90, 3735-3744.	1.5	17
23	Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality. Journal of General Virology, 2016, 97, 839-843.	1.3	10
24	MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters. Frontiers in Microbiology, 2015, 6, 651.	1.5	11
25	Temperature-sensitive mutations for live-attenuated Rift Valley fever vaccines: implications from other RNA viruses. Frontiers in Microbiology, 2015, 6, 787.	1.5	4
26	Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments. Journal of Virology, 2015, 89, 7262-7276.	1.5	56
27	Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factorNSs. Future Virology, 2014, 9, 27-39.	0.9	10
28	Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge. Antiviral Research, 2013, 98, 135-143.	1.9	18
29	Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR. Virology, 2013, 435, 415-424.	1.1	35
30	Characterization of Rift Valley Fever Virus MP-12 Strain Encoding NSs of Punta Toro Virus or Sandfly Fever Sicilian Virus. PLoS Neglected Tropical Diseases, 2013, 7, e2181.	1.3	30
31	Toscana Virus NSs Protein Promotes Degradation of Double-Stranded RNA-Dependent Protein Kinase. Journal of Virology, 2013, 87, 3710-3718.	1.5	36
32	Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis. Journal of Visualized Experiments, 2013, , .	0.2	9
33	Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice. Journal of General Virology, 2013, 94, 1441-1450.	1.3	17
34	The Dominant-Negative Inhibition of Double-Stranded RNA-Dependent Protein Kinase PKR Increases the Efficacy of Rift Valley Fever Virus MP-12 Vaccine. Journal of Virology, 2012, 86, 7650-7661.	1.5	23
35	Modifying theNSsgene to improve live-attenuated vaccine for Rift Valley fever. Expert Review of Vaccines, 2012, 11, 1283-1285.	2.0	14
36	Rift Valley Fever Virus Strain MP-12 Enters Mammalian Host Cells via Caveola-Mediated Endocytosis. Journal of Virology, 2012, 86, 12954-12970.	1.5	77

#	Article	IF	Citations
37	Genetic Subpopulations of Rift Valley Fever Virus Strains ZH548 and MP-12 and Recombinant MP-12 Strains. Journal of Virology, 2012, 86, 13566-13575.	1.5	23
38	Analysis of the humoral immune responses among cynomolgus macaque naturally infected with Reston virus during the 1996 outbreak in the Philippines. BMC Veterinary Research, 2012, 8, 189.	0.7	6
39	Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Research, 2012, 95, 293-310.	1.9	116
40	Functional Analysis of Rift Valley Fever Virus NSs Encoding a Partial Truncation. PLoS ONE, 2012, 7, e45730.	1.1	14
41	Novel approaches to develop Rift Valley fever vaccines. Frontiers in Cellular and Infection Microbiology, 2012, 2, 131.	1.8	39
42	The Pathogenesis of Rift Valley Fever. Viruses, 2011, 3, 493-519.	1.5	282
43	Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy. Journal of Visualized Experiments, 2011, , e3400.	0.2	25
44	Reston Ebolavirus Antibodies in Bats, the Philippines. Emerging Infectious Diseases, 2011, 17, 1559-60.	2.0	85
45	NSs Protein of Rift Valley Fever Virus Promotes Posttranslational Downregulation of the TFIIH Subunit p62. Journal of Virology, 2011, 85, 6234-6243.	1.5	106
46	Rapid Accumulation of Virulent Rift Valley Fever Virus in Mice from an Attenuated Virus Carrying a Single Nucleotide Substitution in the M RNA. PLoS ONE, 2010, 5, e9986.	1.1	39
47	Dual Functions of Rift Valley Fever Virus NSs Protein: Inhibition of Host mRNA Transcription and Postâ€transcriptional Downregulation of Protein Kinase PKR. Annals of the New York Academy of Sciences, 2009, 1171, E75-85.	1.8	65
48	Rift Valley Fever Virus NSs Protein Promotes Post-Transcriptional Downregulation of Protein Kinase PKR and Inhibits eIF2Î± Phosphorylation. PLoS Pathogens, 2009, 5, e1000287.	2.1	195
49	Rift Valley Fever Virus L Protein Forms a Biologically Active Oligomer. Journal of Virology, 2009, 83, 12779-12789.	1.5	32
50	Rift Valley fever vaccines. Vaccine, 2009, 27, D69-D72.	1.7	116
51	Severe Acute Respiratory Syndrome Coronavirus nsp1 Suppresses Host Gene Expression, Including That of Type I Interferon, in Infected Cells. Journal of Virology, 2008, 82, 4471-4479.	1.5	384
52	NSm Protein of Rift Valley Fever Virus Suppresses Virus-Induced Apoptosis. Journal of Virology, 2007, 81, 13335-13345.	1.5	160
53	Characterization of Rift Valley Fever Virus Transcriptional Terminations. Journal of Virology, 2007, 81, 8421-8438.	1.5	48
54	Laboratory Diagnostic Systems for Ebola and Marburg Hemorrhagic Fevers Developed with Recombinant Proteins. Vaccine Journal, 2006, 13, 444-451.	3.2	55

#	Article	IF	Citations
55	Rescue of Infectious Rift Valley Fever Virus Entirely from cDNA, Analysis of Virus Lacking the NSs Gene, and Expression of a Foreign Gene. Journal of Virology, 2006, 80, 2933-2940.	1.5	210
56	NSm and 78-Kilodalton Proteins of Rift Valley Fever Virus Are Nonessential for Viral Replication in Cell Culture. Journal of Virology, 2006, 80, 8274-8278.	1.5	90
57	Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12885-12890.	3.3	386
58	Rift Valley Fever Virus Nonstructural Protein NSs Promotes Viral RNA Replication and Transcription in a Minigenome System. Journal of Virology, 2005, 79, 5606-5615.	1.5	95
59	Rift Valley Fever Virus NSs mRNA Is Transcribed from an Incoming Anti-Viral-Sense S RNA Segment. Journal of Virology, 2005, 79, 12106-12111.	1.5	77
60	Modification of endothelial cell functions by Hantaan virus infection: prolonged hyper-permeability induced by TNF-alpha of hantaan virus-infected endothelial cell monolayers. Archives of Virology, 2004, 149, 1279-92.	0.9	45
61	Detection of immunoglobulin G to Crimean-Congo hemorrhagic fever virus in sheep sera by recombinant nucleoprotein-based enzyme-linked immunosorbent and immunofluorescence assays. Journal of Virological Methods, 2003, 108, 111-116.	1.0	22
62	Analysis of Linear B-Cell Epitopes of the Nucleoprotein of Ebola Virus That Distinguish Ebola Virus Subtypes. Vaccine Journal, 2003, 10, 83-87.	3.2	16
63	Antigen Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Reston Ebola Virus Nucleoprotein. Vaccine Journal, 2003, 10, 552-557.	3.2	32
64	Immunoglobulin G enzyme-linked immunosorbent assay using truncated nucleoproteins of Reston Ebola virus. Epidemiology and Infection, 2003, 130, 533-539.	1.0	21
65	Development of an Immunofluorescence Method for the Detection of Antibodies to Ebola Virus Subtype Reston by the Use of Recombinant Nucleoproteinâ€Expressing HeLa Cells. Microbiology and Immunology, 2002, 46, 633-638.	0.7	20
66	Recombinant Nucleoprotein-Based Enzyme-Linked Immunosorbent Assay for Detection of Immunoglobulin G Antibodies to Crimean-Congo Hemorrhagic Fever Virus. Journal of Clinical Microbiology, 2002, 40, 1587-1591.	1.8	78
67	Chronological and Spatial Analysis of the 1996 Ebola Reston Virus Outbreak in a Monkey Breeding Facility in the Philippines.. Experimental Animals, 2002, 51, 173-179.	0.7	23
68	Histopathology of Natural Ebola Virus Subtype Reston Infection in Cynomolgus Macaques during the Philippine Outbreak in 1996.. Experimental Animals, 2002, 51, 447-455.	0.7	18
69	Immunofluorescence Technique Using HeLa Cells Expressing Recombinant Nucleoprotein for Detection of Immunoglobulin G Antibodies to Crimean-Congo Hemorrhagic Fever Virus. Journal of Clinical Microbiology, 2002, 40, 372-375.	1.8	71
70	Genome structure of Ebola virus subtype Reston: differences among Ebola subtypes. Archives of Virology, 2001, 146, 2021-2027.	0.9	43
71	Detection of Ebola Viral Antigen by Enzyme-Linked Immunosorbent Assay Using a Novel Monoclonal Antibody to Nucleoprotein. Journal of Clinical Microbiology, 2001, 39, 3267-3271.	1.8	77
72	Enterocolitis Associated with Dual Infection byClostridium piliformeand Feline Panleukopenia Virus in Three Kittens. Veterinary Pathology, 1999, 36, 613-615.	0.8	27

#	Article	IF	Citations
73	Naturally Occurring Tyzzer's Disease in a Calf. Veterinary Pathology, 1999, 36, 253-255.	0.8	31